With the substantial expansion of treatment options for castration-resistant prostate cancer (CRPC), including novel hormone therapies, second-generation taxanes, immunotherapy, and bone metastasis-targeted agents, there is a significant need for continuing medical education (CME) to ensure that physicians remain well informed as they seek to optimize treatment for their patients. Assessment data from i3 Health's CME-approved satellite symposium, Castration-Resistant Prostate Cancer: Implementin...

i3 Health's surveys of oncology nurses at the Oncology Nursing Society (ONS) 44 th Annual Congress in Anaheim, California, in April 2019 revealed respondents' preferred formats for continuing nursing education (CNE) activities. The surveys focused on educational needs concerning immune checkpoint inhibitors, cyclin-dependent kinase (CDK)4/6 inhibitors, chimeric antigen receptor (CAR) T-cell therapy, poly (ADP)-ribose polymerase (PARP) inhibitors, and biosimilars. Surveys were completed by 304 on...